ESR1 and breast carcinoma: Lending translational significance to these observations, tumors from mice subjected to dual therapy presented a decrease in the expression of Palbociclib-resistance genes identified in the PALOMA-2/3 and PEARL clinical trials assessing biomarkers of sensitivity and resistance to Palbociclib in ER+ HER− breast cancer [52, 53, 76, 77].